Enzootic Pneumonia (Mycoplasma hyopneumoniae)

Enzootic pneumonia is a chronic respiratory disease of swine caused by Mycoplasma hyopneumoniae (M. hyo or MHP), a small, wall-less bacterium that colonizes the respiratory epithelium and causes persistent lung damage. This condition represents one of the most economically important diseases in global swine production, causing significant reductions in growth rate and feed efficiency even in the absence of obvious clinical signs. The term "enzootic" reflects the endemic, continuously present nature of this infection in most conventional swine herds worldwide, distinguishing it from epidemic diseases that occur as discrete outbreaks.

Mycoplasma hyopneumoniae infection occurs globally and is present in the majority of commercial swine operations, with prevalence rates exceeding 80% in many surveys of conventional herds. The organism is uniquely adapted to swine and does not infect other species. Infection is typically introduced through purchase of infected breeding stock or contact with contaminated personnel, equipment, or aerosols. Once established in a herd, M. hyo becomes endemic and is maintained through ongoing transmission from infected sows to piglets and between pigs during the growing period.

The economic impact of enzootic pneumonia is substantial despite the relatively mild clinical signs typically observed. Studies consistently demonstrate that M. hyo-infected pigs have reduced average daily gain of 2-10% and impaired feed conversion efficiency of 2-10% compared to uninfected counterparts. These performance losses translate to significant economic costs when multiplied across large production systems. Additionally, M. hyo infection predisposes pigs to secondary bacterial infections, acting as a primary component of the Porcine Respiratory Disease Complex (PRDC) that causes more severe clinical disease and greater losses.

Control of enzootic pneumonia has evolved significantly, with options ranging from conventional management and vaccination to complete elimination programs. Vaccination reduces clinical disease and improves performance but does not eliminate infection or prevent transmission. Strategic medication programs can suppress clinical signs during critical growth periods. Increasingly, producers are pursuing M. hyo elimination strategies that can be achieved through careful management protocols, offering the potential for herds free of this significant production-limiting pathogen.

Mycoplasma hyopneumoniae is a small, pleomorphic bacterium belonging to the class Mollicutes, characterized by the absence of a cell wall. This unique structural feature makes the organism intrinsically resistant to beta-lactam antibiotics and other cell wall-active antimicrobials. The organism has a small genome with limited metabolic capabilities, making it dependent on host cells for many essential nutrients. M. hyo is fastidious and slow-growing in culture, requiring specialized media and extended incubation times of up to 4-6 weeks for isolation, which historically complicated diagnosis and research.

Transmission of M. hyo occurs primarily through direct nose-to-nose contact between infected and susceptible pigs, with respiratory secretions containing infectious organisms. The most important transmission route is from infected sows to piglets during the nursing period, establishing infection early in life. Pig-to-pig transmission continues during the nursery and growing periods as infected animals spread the organism to susceptible penmates. Unlike many respiratory pathogens, M. hyo spreads relatively slowly within populations, with an estimated basic reproduction number lower than many other swine pathogens.

Aerosol transmission can occur over distances of several kilometers under favorable environmental conditions, presenting challenges for maintaining M. hyo-negative herds in swine-dense regions. The organism can survive in aerosols for extended periods, particularly in cool, humid conditions. This capacity for long-distance airborne spread has significant implications for regional disease control and necessitates consideration of farm location and air filtration when attempting elimination or maintaining negative status.

Risk factors for M. hyo transmission and disease expression include herd infection status, management practices, and environmental conditions. Continuous flow management systems maintain ongoing transmission between age groups, while all-in-all-out systems can break transmission cycles. High stocking density increases contact rates and accelerates spread. Poor air quality with elevated ammonia, dust, and temperature fluctuations damages respiratory defenses and exacerbates disease. Co-infections with PRRS virus, swine influenza, and bacterial pathogens significantly worsen clinical outcomes in M. hyo-infected herds.

The pathogenesis of enzootic pneumonia involves adhesion of M. hyo to respiratory epithelial cells via specialized adhesins, followed by ciliary destruction and inflammation. The organism attaches specifically to cilia on tracheal and bronchial epithelium, causing ciliostasis and eventual loss of ciliated cells. This damage impairs mucociliary clearance, the primary defense mechanism for removing inhaled particles and pathogens from the airways. The resulting accumulation of mucus and debris, combined with inflammatory cell infiltration, creates the characteristic lesions of enzootic pneumonia. The epithelial damage and immune modulation caused by M. hyo predispose to colonization and invasion by secondary bacterial pathogens.

Early warning signs of enzootic pneumonia are often subtle and may go unnoticed in busy production settings. A mild, dry, nonproductive cough may be heard sporadically in affected groups, particularly when pigs are active or disturbed. This cough is often described as the classic "barking" cough of mycoplasmal pneumonia. Slightly reduced feed intake may be observed before more obvious respiratory signs develop. Individual pigs may appear slightly less thrifty than penmates without obvious cause. These early signs are easily overlooked and frequently not recognized until retrospective assessment after diagnosis.

Common symptoms develop gradually as infection progresses and lung damage accumulates. Chronic nonproductive coughing becomes more frequent and persistent, affecting a growing proportion of the group over weeks to months. Coughing episodes are often triggered by activity, disturbance, or changes in temperature and humidity. Affected pigs may show decreased growth rate that becomes apparent when compared to expected performance or unaffected groups. Feed conversion efficiency declines, meaning pigs require more feed per unit of gain. Respiratory rate may be slightly elevated, and pigs may show reduced exercise tolerance.

Behavioral changes in pigs with enzootic pneumonia reflect chronic respiratory compromise and reduced vitality. Affected animals may show decreased activity levels and reduced willingness to compete at feeders. Pigs may seek cooler areas of the pen due to impaired ability to dissipate heat through normal respiratory function. Slower eating patterns and reduced meal sizes may be observed. Despite these behavioral changes, severely ill-appearing pigs are uncommon in uncomplicated enzootic pneumonia, which distinguishes it from more acute respiratory diseases.

Physical examination findings in M. hyo-infected pigs are often minimal despite significant underlying lung pathology. Auscultation may reveal increased bronchovesicular sounds or wheezes in affected lung regions, though findings can be subtle. Fever is typically absent or low-grade in uncomplicated cases. Body condition may decline slightly due to reduced feed efficiency. The relatively mild clinical presentation compared to lung lesion severity is a hallmark of enzootic pneumonia, with significant pathology often discovered unexpectedly at slaughter.

Symptom progression in enzootic pneumonia follows a chronic course over weeks to months rather than the rapid progression seen in acute respiratory diseases. Initial infection during the nursing or early post-weaning period may produce minimal signs. Clinical evidence of disease typically becomes most apparent during the late nursery through mid-finishing period when lung lesions reach peak severity. As pigs mature and mount immune responses, clinical signs often diminish, though performance impacts persist. The subclinical nature of much M. hyo infection means that significant economic losses occur without obvious clinical disease.

Emergency symptoms occur when secondary bacterial infections complicate primary mycoplasmal pneumonia, resulting in more severe clinical presentations. Development of high fever, severe dyspnea, cyanosis, or sudden mortality suggests secondary infection with pathogens such as Actinobacillus pleuropneumoniae, Pasteurella multocida, or Streptococcus suis. Rapid progression from mild coughing to severe respiratory distress warrants immediate veterinary attention and aggressive treatment. These complications represent the more severe manifestations of Porcine Respiratory Disease Complex in which M. hyo plays a predisposing role.

Clinical diagnosis of enzootic pneumonia is based on recognition of chronic coughing in growing pigs combined with epidemiological evidence of endemic respiratory disease. The characteristic dry, nonproductive cough affecting multiple animals over extended periods is suggestive but not pathognomonic. Slaughter surveillance revealing cranioventral lung consolidation supports clinical suspicion. History of M. hyo-positive herd status or introduction of animals from positive sources adds epidemiological context. However, clinical diagnosis alone cannot distinguish M. hyo from other causes of chronic respiratory disease, necessitating laboratory confirmation.

Laboratory diagnosis of M. hyo infection employs several complementary methods with different applications. Polymerase chain reaction (PCR) testing provides sensitive and specific detection of M. hyo DNA in clinical samples including lung tissue, laryngeal swabs, tracheobronchial lavage fluid, and oral fluids. PCR is the method of choice for rapid, accurate diagnosis and can be performed on pooled samples for cost-effective herd screening. Culture of M. hyo is possible but requires specialized media and prolonged incubation of 4-6 weeks, limiting its practical utility for routine diagnosis.

Serological testing detects antibodies against M. hyo using enzyme-linked immunosorbent assay (ELISA) and provides information about exposure history rather than active infection. Seroconversion typically occurs 3-6 weeks after infection, making serology useful for monitoring herd status and timing of exposure but not for early detection. Strategic sampling of different age groups can characterize infection dynamics within herds. Serology cannot distinguish vaccinated animals from naturally infected ones, requiring interpretation in context of vaccination history.

Slaughter surveillance with systematic lung lesion scoring provides valuable population-level assessment of M. hyo disease impact. The characteristic lesions of mycoplasmal pneumonia—purple-gray consolidation affecting the cranioventral lung lobes bilaterally—are highly suggestive of M. hyo etiology. Lesion scoring systems grade the percentage of lung tissue affected, enabling standardized monitoring over time. This approach quantifies subclinical disease burden that may not be apparent from clinical observation alone. Combining slaughter surveillance with PCR testing of lung samples confirms etiology and validates clinical lesion attribution.

Differential diagnosis includes other causes of chronic coughing and cranioventral lung consolidation in growing pigs. Swine influenza can cause similar lesions but typically presents as acute epidemic outbreaks rather than endemic disease. Actinobacillus pleuropneumoniae causes more dorsocaudal lesions with different character. PRRS causes interstitial pneumonia with different lesion distribution. Bordetella bronchiseptica and Pasteurella multocida may cause similar lesions as secondary invaders. Comprehensive diagnostic workup often identifies M. hyo in combination with other pathogens, reflecting the polymicrobial nature of swine respiratory disease.

Treatment of enzootic pneumonia focuses on controlling clinical signs and limiting performance impacts, as complete elimination of infection from individual animals is difficult to achieve. Antimicrobial therapy can suppress M. hyo proliferation and reduce clinical disease, but does not typically clear the organism from infected pigs due to its intracellular location and the absence of a cell wall that renders beta-lactams ineffective. Treatment is most beneficial when initiated early in the disease course before extensive lung damage has developed.

Antimicrobial selection for M. hyo must consider the organism's unique biology and resistance patterns. Macrolides including tylvalosin, tilmicosin, and tylosin have good activity against mycoplasmas and penetrate respiratory tissues effectively. Fluoroquinolones such as enrofloxacin and marbofloxacin are also effective. Tetracyclines including chlortetracycline and oxytetracycline provide cost-effective options for mass medication. Pleuromutilins including tiamulin and valnemulin have excellent antimycoplasmal activity. Lincosamide antibiotics including lincomycin are additional options. Drug selection should consider susceptibility patterns, withdrawal times, and cost-effectiveness for the specific production system.

Strategic medication programs target high-risk periods when clinical disease expression is likely. Prophylactic medication during the post-weaning period can reduce early disease development. Metaphylactic treatment of groups during respiratory disease outbreaks limits clinical impacts. Pulse medication programs provide intermittent coverage during the growing period. These strategic approaches are more sustainable than continuous medication and support antimicrobial stewardship objectives while maintaining disease control.

Supportive care complements antimicrobial treatment and optimizes conditions for recovery. Environmental management to reduce respiratory irritants including ammonia and dust supports respiratory health. Adequate ventilation without drafts maintains air quality. Temperature control prevents thermal stress that can exacerbate respiratory disease. Reducing stocking density decreases transmission pressure and improves per-pig resources. These management interventions benefit overall respiratory health beyond M. hyo-specific effects.

Herd treatment protocols during outbreaks of clinical enzootic pneumonia combine individual treatment of severely affected animals with population-level interventions. Water medication provides rapid delivery of antimicrobials to clinically ill animals that may have reduced feed intake. Feed medication offers sustained coverage for longer treatment courses. Injectable treatment addresses individual animals with more severe disease. Concurrent vaccination can accelerate development of protective immunity. These combined approaches typically bring clinical disease under control within 2-4 weeks.

Treatment decisions should recognize the limitations of antimicrobial therapy for enzootic pneumonia and the potential benefits of alternative strategies. Vaccination provides longer-term protection than antimicrobial treatment alone. Elimination programs offer the possibility of permanent freedom from M. hyo infection. Economic analysis comparing treatment costs to prevention investments and production impacts helps optimize resource allocation. Working with the herd veterinarian to develop comprehensive respiratory health programs maximizes outcomes and minimizes antimicrobial use.

Recovery from acute episodes of enzootic pneumonia typically occurs over 2-4 weeks as antimicrobial treatment and developing immunity bring clinical signs under control. Coughing frequency decreases progressively, though some residual coughing may persist. Feed intake and growth rate improve as respiratory function recovers. However, lung lesions representing permanent damage persist and may continue to affect performance even after clinical recovery. Complete elimination of M. hyo infection from individual animals is not reliably achieved, and many pigs remain colonized despite clinical improvement.

Post-treatment monitoring should assess both clinical recovery and performance restoration. Reduction in coughing frequency and severity indicates successful clinical response. Feed consumption records document return to normal intake patterns. Growth rate comparison to unaffected groups or expected targets quantifies residual performance impact. Continued monitoring through the finishing period identifies any recurrence of clinical disease. Slaughter surveillance provides final assessment of lung lesion burden and disease impact.

Prognosis for individual animals is generally favorable for survival but variable for return to optimal performance. Uncomplicated enzootic pneumonia rarely causes mortality in growing pigs. However, performance recovery depends on extent of lung damage at the time of treatment. Pigs with extensive lesions may never fully recover normal growth rates and feed efficiency. Animals that develop secondary bacterial complications have more guarded prognosis and may experience more severe performance impacts. Overall, affected groups typically reach market weight but may require additional time and feed compared to unaffected groups.

Return to production at the herd level focuses on preventing ongoing losses in subsequent pig groups rather than fully recovering losses in already affected animals. Implementing or optimizing vaccination programs protects future groups from similar losses. Management changes addressing predisposing factors reduce disease expression. For herds pursuing elimination, successful eradication enables production free of M. hyo-associated losses. Economic analysis should account for both immediate treatment costs and ongoing production impacts when evaluating control program options.

Vaccination against M. hyo is widely practiced and represents the primary prevention strategy in most commercial swine operations. Commercial bacterin vaccines containing killed M. hyo organisms stimulate immunity that reduces clinical disease and improves growth performance. Single-dose and two-dose protocols are available, with administration typically at or after weaning. Intradermal needle-free delivery systems offer labor-efficient administration for large populations. While vaccination reduces disease severity and economic impact, it does not prevent infection or eliminate the organism, so vaccinated herds remain positive for M. hyo.

Biosecurity measures prevent introduction of M. hyo into negative herds and reduce transmission in positive herds. External biosecurity focuses on sourcing replacement animals from M. hyo-negative or known-status herds with quarantine and testing before introduction. Gilt acclimation programs in positive herds ensure replacements are exposed and immune before entering the breeding herd. Air filtration can reduce risk of aerosol introduction, though investment costs are significant. Internal biosecurity including all-in-all-out management and segregated production reduces transmission between age groups.

M. hyo elimination is increasingly pursued as producers recognize the long-term benefits of negative status. Elimination strategies include herd closure with extended exposure period followed by cessation of transmission to piglets (load-close-expose), partial depopulation approaches that remove the sow herd and repopulate with negative stock, and complete depopulation with cleaning and restocking. Medication protocols can support elimination by reducing shedding during the exposure period. Success rates are high when protocols are followed carefully, with many herds achieving and maintaining negative status.

Environmental management supports respiratory health and reduces M. hyo disease expression in positive herds. Ventilation systems should maintain air quality with minimal ammonia, dust, and pathogens. Temperature stability without extreme fluctuations reduces respiratory stress. Stocking density management limits transmission pressure. Pig flow designs that minimize mixing and provide age segregation interrupt transmission chains. These factors influence disease severity even when infection cannot be prevented.

Monitoring and surveillance maintain awareness of herd M. hyo status and enable early detection of problems. Routine serological profiling characterizes exposure timing and dynamics. PCR testing of oral fluids provides efficient population-level monitoring. Slaughter surveillance with lung lesion scoring quantifies disease burden. Tracking these parameters over time enables evaluation of control program effectiveness and early detection of any changes in disease status.

Daily management and monitoring for enzootic pneumonia emphasizes attention to respiratory signs in growing pigs and objective tracking of performance parameters. Farm personnel should note the frequency and character of coughing during daily observations, as changes may indicate evolving disease status or intervention needs. Feed disappearance monitoring can detect decreases in consumption that may precede obvious clinical signs. Daily mortality and morbidity checks identify animals requiring individual attention. Documentation of observations supports trend analysis and program evaluation.

Housing and environmental management directly impact M. hyo transmission and disease expression. Ventilation systems require regular maintenance and adjustment to maintain optimal air quality across seasons. Target environmental parameters include ammonia below 25 ppm, temperature appropriate for pig age and weight, and minimal dust levels. Flooring and manure management affect air quality through waste gas emissions. Building design should facilitate all-in-all-out management with complete cleanout between groups. Investment in environmental control provides returns through reduced respiratory disease.

Herd health programs for M. hyo integrate vaccination, medication, management, and monitoring components. Vaccination protocols specify products, timing, and target populations based on herd-specific disease patterns. Medication strategies define products, timing, and indications for prophylactic, metaphylactic, and therapeutic use. Management standards address environmental conditions, pig flow, and biosecurity. Monitoring programs include clinical observation, performance tracking, and diagnostic testing. Regular veterinary review evaluates program effectiveness and identifies optimization opportunities.

Record keeping supports M. hyo management through documentation of health events, interventions, and outcomes. Vaccination records confirm protocol compliance and enable correlation with disease occurrence. Treatment records support antimicrobial stewardship and withdrawal time compliance. Diagnostic test results track herd status over time. Performance data by group documents disease impacts and intervention effectiveness. Mortality and slaughter records provide outcome measures. Integrated data management enables comprehensive analysis.

Economic considerations in M. hyo management include assessment of disease costs and evaluation of control investments. Calculating production losses due to reduced growth rate and feed efficiency quantifies disease impact. Comparing vaccination, medication, and elimination strategies identifies most cost-effective approaches for specific operations. Return on investment analysis for biosecurity improvements and environmental upgrades guides capital allocation. Working with veterinarians, production advisors, and economists optimizes control program design for economic as well as health outcomes.

All breeds and genetic lines of domestic swine are susceptible to Mycoplasma hyopneumoniae infection, with no breeds demonstrating natural resistance. The organism has co-evolved with swine and efficiently infects all commercial breeds and genetic lines regardless of origin or selection history. Modern high-lean commercial genetics, heritage breeds, and experimental miniature pig lines all develop typical enzootic pneumonia when infected. While individual variation in disease severity exists, breed does not significantly influence susceptibility or clinical outcomes compared to management and environmental factors.

Production type and management system have greater influence on M. hyo disease expression than genetic background. Continuous flow operations with ongoing transmission between age groups maintain higher infection pressure than batch-farrowing all-in-all-out systems. Multi-site production with age-segregated rearing can reduce disease expression even in positive systems. Outdoor and extensive production may have different disease dynamics than intensive confinement, though M. hyo can infect pigs in any system. High-health breeding herds increasingly pursue M. hyo-negative status to provide customers with negative replacement stock.

Genetic selection has not specifically targeted M. hyo resistance, though general selection for disease resilience and immune competence may provide indirect benefits. Breeding companies do not offer M. hyo-resistant genetic lines. Research has explored genetic variation in response to M. hyo infection, with some evidence for heritable differences in lesion severity and antibody responses. However, practical application of genetic selection for M. hyo resistance remains limited. Producers should focus on management, vaccination, and elimination strategies rather than genetic approaches for M. hyo control.

Commonly co-occurring conditions with enzootic pneumonia include other components of the Porcine Respiratory Disease Complex (PRDC). Porcine Reproductive and Respiratory Syndrome (PRRS) virus frequently co-infects M. hyo-positive herds and significantly worsens respiratory disease severity and duration. Swine influenza virus causes periodic outbreaks that can be more severe in M. hyo-infected populations. Actinobacillus pleuropneumoniae, Pasteurella multocida, Streptococcus suis, and Haemophilus parasuis commonly cause secondary bacterial infections in M. hyo-damaged lungs. The combination of M. hyo with one or more of these pathogens causes clinical disease far more severe than M. hyo alone.

Conditions with similar clinical presentations require differentiation from enzootic pneumonia. Swine influenza causes acute respiratory disease with coughing but typically presents as epidemic outbreaks rather than endemic chronic disease. Actinobacillus pleuropneumoniae causes more severe acute disease with different lesion distribution. PRRS causes interstitial pneumonia with systemic effects. Atrophic rhinitis affects upper respiratory tract rather than lungs. Parasitic pneumonia from migrating ascarid larvae may cause coughing and lung lesions. Comprehensive diagnostic workup identifies specific pathogens and their relative contributions to respiratory disease.

Complications and sequelae of enzootic pneumonia relate to the chronic lung damage and predisposition to secondary infections that characterize this disease. Permanent lung lesions persist even after clinical recovery and continue to impair respiratory efficiency. Colonization of M. hyo-damaged airways by secondary bacterial pathogens causes more severe clinical disease than primary M. hyo infection. Chronic respiratory compromise reduces heat tolerance and exercise capacity. Performance impacts including reduced daily gain and feed efficiency persist throughout the growing period. These chronic effects emphasize the value of prevention strategies including vaccination and elimination programs.